We read with keen interest the letter by Banerjee et al 1 titled 'Routine use of topical cyclopentolate as a predisposing factor to recurrent urinary tract infections in a susceptible adult'. As highlighted, cyclopentolate eyedrops can have serious systemic effects, more so in children. We just wish to highlight that it should be used with caution in children. Some of the methods to decrease the chances of toxicity include avoiding overdosage, punctal occlusion following application, and avoiding high ambient temperature and humidity 2 . The use of microdrops (5 ml) as compared with normal drops (35 ml) could also reduce the incidence of side effects 3 . Other options include diluted cyclopentolate or safer drugs such as tropicamide and homatropine (2%).
Sir, Comment on: How common is inflammatory marker-negative disease in giant cell arteritis?
We read with interest the report by Dr Levy and colleagues 1 about a case of giant cell arteritis (GCA) with normal C-reactive protein (CRP). The studies reviewed by the authors indicate that this is an unusual finding. However, the authors' inadvertent omission of two recent articles evaluating laboratory predictors of a positive temporal artery biopsy is potentially misleading. 2, 3 The study by Parikh et al 4 used a much lower cut-off for normal CRP of 5 mg/l, which may be the reason for the high sensitivity of CRP reported in their study. In the study by Walvick and Walvick, 2 a CRP cut-off of 5 mg/l yielded a sensitivity of 94.9%, which means that 5.1% had a falsely normal CRP (less than 5 mg/l). In our study of 764 patients who underwent temporal artery biopsy, the sensitivity of CRP for GCA was 86.4%. 3 In other words, 13.6% patients had a normal CRP (less than 8 mg/l in our laboratory), a much higher percentage than previously reported. Therefore, normal CRP does not exclude GCA in a patient with high clinical suspicion such as the case reported by Levy and colleagues. 1 We would also suggest that the case reported by Levy and colleagues 1 had an elevated erythrocyte sedimentation rate (ESR) and therefore would more appropriately be considered 'CRPnegative' rather than 'inflammatory marker-negative disease'. True 'inflammatory marker-negative disease' (ie, both ESR and CRP normal) is rare but was observed in 4% (seven patients) in our study. 3 In summary, the currently available biomarkers for diagnosis of GCA (ie, ESR and CRP) are imperfect given the less than desired sensitivity and poor specificity. Additionally, while studies evaluating these biomarkers provide us with aggregate results about a group of patients, they remain suboptimal when considering an individual patient presentation. Regardless of laboratory evaluation, in patients with high clinical suspicion for GCA we believe a temporal artery biopsy should be pursued as was done by Dr Levy and colleagues 1 to establish the diagnosis.
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In response to their comments on our report 2 we acknowledge the inadvertent omission of two recent articles, 3, 4 both of which emphasise the occurrence of CRP-negative disease seen in giant cell arteritis (GCA). Our case is clearly described as 'CRP-negative disease', and in addition to this we review inflammatory-markernegative disease in GCA, as it is appropriate and informative in this context.
The threshold for an abnormal CRP result is ill defined. Indeed various receiver operating characteristic curves for CRP have been published, illustrating the trade-off of sensitivity and specificity at various threshold settings. Also, different laboratories express the parameter as either mg/l or mg/dl, which can be a source of confusion in clinical practice. Hayreh et al 5 use a level o24.5 mg/l (2.45 mg/dl) as a cut-off for normal in the context of GCA.
